|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||369.00 - 378.60|
|52-week range||308.57 - 390.01|
|Beta (5Y monthly)||0.25|
|PE ratio (TTM)||20.90|
|Forward dividend & yield||9.78 (2.64%)|
|Ex-dividend date||18 Mar 2021|
|1y target est||N/A|
J&J (JNJ) and Novartis (NVS) announce Q2 results. FDA delays decisions on JAK inhibitor drugs of Lilly (LLY), AbbVie (ABBV) and Pfizer (PFE) for eczema indication.
Roche's (RHHBY) performance in first-half 2021 was impressive on strong demand for new medicines and COVID-19 test kits. Impact of biosimilars continues to hurt sales.
Regeneron's(REGN) cocktail for the treatment of COVID-19 gets approval in Japan as Ronapreve.